{"entity":{"id":"sgr-1505","kind":"drug","name":"SGR-1505","aka":[],"tldr":"SGR-1505 is an experimental small molecule from Schrödinger, in phase 1 trials for relapsed or refractory B-cell malignancies, waldenström macroglobulinaemia and chronic lymphocytic leukaemia and other cancers.","summary":"SGR-1505 is a small molecule (oral) from Schrödinger. An inhibitor of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), which the company describes as a key mediator of the NF-κB signalling pathway and the main driver of a subset of B-cell lymphomas. Its furthest stage is phase 1, for relapsed or refractory B-cell malignancies, waldenström macroglobulinaemia, chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. 10-Q for the quarter to 30 June 2026 (filed 5 August 2026): Schrödinger will complete the ongoing phase 1 dose-escalation trial, does not intend to start further trials independently, and plans to seek strategic partners. FDA Fast Track (June 2025) for relapsed/refractory Waldenström macroglobulinaemia after at least two lines including a BTK inhibitor. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Schrödinger: schrodinger.com","url":"https://www.schrodinger.com/pipeline/"},{"label":"Schrödinger: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm"},{"label":"Schrödinger: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm"},{"label":"Schrödinger: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097826000068/sdgr-20260630.htm"},{"label":"ClinicalTrials.gov: trials of SGR-1505","url":"https://clinicaltrials.gov/search?intr=SGR-1505"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","waldenstrom","cll","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["malt1"],"drugs":[],"companies":["schrodinger"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05544019"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SGR-1505","modality":"Small molecule (oral)","mechanism":"An inhibitor of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), which the company describes as a key mediator of the NF-κB signalling pathway and the main driver of a subset of B-cell lymphomas.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sgr-1505/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"target":[{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/"}],"company":[{"id":"schrodinger","kind":"company","name":"Schrödinger","route":"/companies/schrodinger/"}],"trial":[{"id":"nct05544019","kind":"trial","name":"Study of SGR-1505 in Mature B-Cell Neoplasms","route":"/trials/nct05544019/"}]}}